Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism

KSHV-associated cancers have poor prognoses and lack therapeutics that selectively target viral gene functions. We developed a screening campaign to identify known drugs that could be repurposed for the treatment of KSHV-associated cancers. We focused on primary effusion lymphoma (PEL), which has pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Calderon, Abram, Soldan, Samantha S., De Leo, Alessandra, Deng, Zhong, Frase, Drew M., Anderson, Emma M., Zhang, Yue, Vladimirova, Olga, Lu, Fang, Leung, Jessica C., Murphy, Maureen E., Lieberman, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679036/
https://www.ncbi.nlm.nih.gov/pubmed/33245718
http://dx.doi.org/10.18632/oncotarget.27815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679036/
https://www.ncbi.nlm.nih.gov/pubmed/33245718
http://dx.doi.org/10.18632/oncotarget.27815

Ejemplares similares